
Zydus Q2 FY27: PAT falls 25% YoY to ₹925 Cr, below Street, as M&A-led revenue surges 29%
pharmaceuticals · margin compression · acquisition integration

pharmaceuticals · change of control · customer termination

pharmaceuticals · seasonal demand · margin expansion

fmcg · otc pharma · pain relief balms

crdmo · margin expansion · speciality ingredients

pharmaceuticals · parenteral solutions · margin expansion

INR500 acquisition strategy · organic underperformance · hospital channel entry

hospital services · margin expansion · revenue growth

senior living · assisted care · holding company

pharma cdmo · api manufacturer · margin compression

earnings · margin compression · API growth

API-led growth 30% YoY · Gross margin compression 400 bps · Immunosuppressant momentum

battery-grade iron phosphate · margin expansion · specialty ingredients recovery

battery-grade iron phosphate · greenfield FDA approval · magnesium bisglycinate

pharmaceuticals · crop protection · margin expansion

hospital chain · healthcare · margin compression

margin expansion · international growth · guidance beat

DDC capacity ramp · semaglutide supply · line 3 delay

pharmaceuticals · api · profit turnaround

DDC expansion · semaglutide commercialization · biologics MSA wins

CDMO growth · capex intensity · peptide validation

CDMO 86% growth · peptide validation · ₹3K capex raise

cdmo growth · margin expansion · pat surge

pharmaceuticals · generics · margin compression

CMO inflection · margin compression · Innoxel licensing

commercial inflection · CMO export · material cost inflation

order book · margin expansion · geopolitical headwind

order book · margin expansion · geopolitical headwind

diagnostics · margin compression · rajasthan ramp-up

pharmaceuticals · margin expansion · standalone results